Journal

Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide

Read time: 1 mins

Published:1st Mar 2017

Author: De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A et al.

Source: Advances in Therapy

Availability: Free full text

Ref.:Adv Ther. 2017;34(3):620-637

DOI:10.1007/s12325-017-0488-9

Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin.

Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

Read abstract on library site Access full article